<p>Predicted neutralization sensitivity of non-B subtype HIV-1 variants to bNAbs over time. <b>A</b> - <b>D</b>: the predicted neutralization sensitivity of HIV-1 samples of the non-B subtype to the bNAbs 3BNC117, 35O22, PGT121, and PG16. <b>E</b>: the ratio of R5-tropic and X4-capable non-B subtype HIV-1 variants in the Los Alamos HIV sequence database over the six time periods. <b>F</b>: predicted neutralization sensitivity of R5-tropic variants of the non-B subtype to PG16.</p
International audienceUNLABELLED: ABSTRACT: BACKGROUND: HIV-1 subtype D infections have been associa...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
For each neutralizing antibody (NAb), the geometric mean (GM) IC50 and percentage of pseudoviruses (...
Susceptibility to autologous and heterologous neutralization of primary human immunodeficiency virus...
Neutralization potencies of 33 subtype B HIV+ plasma samples collected in the 1990s, 2000s and 2010s...
Neutralization sensitivities of contemporary U.S. subtype B pseudoviruses (PSVs) (2017–18) were comp...
Despite the fact that over 90% of HIV-1 infected people worldwide harbor non‑subtype B variants of H...
a<p>This estimate is based on published data and methods for estimating time of infection as describ...
<p>[A to E] Comparison of the neutralization sensitivity of Env-pseudotyped viruses derived from his...
Graphical plot showing the comparison of neutralization sensitivities to several bNAbs of viruses fr...
To assess the molecular epidemiology of human immunodeficiency virus type 1 (HIV-1), a screening met...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
Pseudoviruses were categorized by infection stage to demonstrate differences in neutralization sensi...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: HIV-1 subtype D infections have been associa...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...
For each neutralizing antibody (NAb), the geometric mean (GM) IC50 and percentage of pseudoviruses (...
Susceptibility to autologous and heterologous neutralization of primary human immunodeficiency virus...
Neutralization potencies of 33 subtype B HIV+ plasma samples collected in the 1990s, 2000s and 2010s...
Neutralization sensitivities of contemporary U.S. subtype B pseudoviruses (PSVs) (2017–18) were comp...
Despite the fact that over 90% of HIV-1 infected people worldwide harbor non‑subtype B variants of H...
a<p>This estimate is based on published data and methods for estimating time of infection as describ...
<p>[A to E] Comparison of the neutralization sensitivity of Env-pseudotyped viruses derived from his...
Graphical plot showing the comparison of neutralization sensitivities to several bNAbs of viruses fr...
To assess the molecular epidemiology of human immunodeficiency virus type 1 (HIV-1), a screening met...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
Pseudoviruses were categorized by infection stage to demonstrate differences in neutralization sensi...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: HIV-1 subtype D infections have been associa...
Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and n...
Antiretroviral treatment of Human Immunodeficiency Virus type-1 (HIV-1) infections with CCR5-antagon...